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Abstract
Background: Registration of trigger factors, prodromal symptoms, swelling localization, therapeutic behavior and
gender-specific differences of the largest cohort of patients with hereditary angioedema due to C1-Inhibitor
deficiency (C1-INH-HAE) in Switzerland.
Methods: Questionnaire survey within a cohort study: Consenting eligible patients with diagnosed HAE according to
clinical history, physical examination and laboratory results, including plasma values for C1-INH and C4 were selected.
To each participant we sent a questionnaire assessing patients’ birthday, sex, date of first symptoms and diagnosis,
trigger factors, prodromal symptoms, frequency and localization of angioedema, medication use and co-morbidities.
Clinical information was collected in each center and then transmitted to the cohort database. Frequencies and
distributions were summarized. Associations between gender and trigger factors or prodromal symptoms or
localization of angioedema were assessed in multivariate analyses correcting for patients’ age.
Results: Of 135 patients, data from 104 patients (77 %) were available for analysis. Fifty- four percent were female,
mean age at diagnosis was 19.5 years (SD 14.1), Mean age when completing the questionnaire was 44.0 (SD 19.8).
More women than men were symptomatic (44/57 vs. 36/47; p = 0.005). This association remained when correcting for
age at diagnosis (16.10. 95%CI (5.17 to 26.70); p = 0.004). Swelling episodes ranged between 1 and 136 episodes/year.
Swelling was more common among female than among male (-13.15 (95 % CI; -23.10 to -3.22), p = 0.010). Age at
diagnosis was inversely associated with the total number of attacks 0.50 (-0.88 to -.011); p = 0.012). One third of patients
were on danazol prophylaxis.
Conclusion: We found large differences of HAE in male and female both in terms of symptom number and swelling
episodes. Women are more affected by intensity and frequency of angioedema episodes than men. Danazol treatment
remains widely used as effective prophylaxis despite its side effects. New therapies which selectively influence the
hormonal estrogen balance could open new therapeutic options mainly for women and maybe also for men.
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Background
Hereditary angioedema with C1 inhibitor deficiency (C1-
INH-HAE) is a rare, inherited disease, clinically charac-
terized by recurrent acute swelling episodes on the ex-
tremities, abdomen, face, trunk, or airways, resulting
from increased vascular permeability. These episodes
occur spontaneously or are triggered by stimuli such as
trauma, psychological stress, or infections. The swellings
in HAE patients are highly variable in terms of trigger
factors, severity, frequency and location [1, 2].
There are two types of C1-INH-HAE: Type I with de-
creased secretion of C1 inhibitor protein and Type II
with secretion of a dysfunctional protein [3, 4]. Both re-
sult from an aberration in the gene coding for the
plasma protein C1-inhibitor (C1-INH). Another type of
HAE with normal C1-INH protein was first described in
1985. In some of these patients a mutation in F12 gene
can be detected and they are classified FXII-HAE, the
other patients without detection of a genetic defect are
classified unknown HAE (U-HAE) [3–5]. According to
several nationwide cohort studies the prevalence of HAE
is estimated to be between 1:50000 and 1:100000 [6–9].
In Switzerland three studies describing the clinical char-
acteristics of patients with HAE have been published so
far [10–12]. Switzerland with approximately 8 million in-
habitants is divided in four different language regions.
The German part with about 70 % inhabitants, the
French part (23 %), Italian part (6 %) and Rumantsch
part (1 %). The present study is based on 135 patients
living in the German part. Based on the estimated preva-
lence, the number of patients in our Swiss cohort corre-
sponds to approximately 85 % of all HAE-affected
patients living in Switzerland and thus represents the
most complete set.
It is known that women suffer from more frequent
and more severe angioedema attacks than men [13]. In
this study, expanding on previous research, [13] we ana-
lyzed gender specific differences of HAE in more detail
comparing trigger factors, prodromal symptoms, swell-
ing localization and therapeutic behavior on women and
men. Finally, we discuss treatment plans for different
disease manifestations.
Methods
The protocol of this study received Ethics approval and
was conducted according to the principles of good clin-
ical practice and strictly adhered to the ethical standards
outlined in the Declaration of Helsinki [14].
Identification of patients
Patients from the Division of Haematology of the Can-
tonal Hospital Lucerne, the Allergy Units of the Univer-
sity Hospitals from Zurich, Berne and Basel were
included. All patients fulfilling the diagnostic guidelines
criteria for HAE [3, 15] qualified for inclusion. All in-
cluded patients gave their written informed consent. Pa-
tients from the French and Italian part of Switzerland
were excluded because Ethics approval for this study
was missing.
Data collection
HAE was diagnosed on the basis of patient history, clin-
ical examination and laboratory results, including
plasma levels of functional C1-INH, antigenic C1-INH
and complement factor C4. C1-INH-HAE type I was di-
agnosed when C4 was decreased and functional and
antigenic C1-INH levels were below 50 % of normal. C1-
INH HAE type II was diagnosed when C4 was de-
creased, functional C1-INH was below 50 % and anti-
genic C1-INH was above 50 % of normal. In 2013 a
detailed questionnaire was sent to the participants,
assessing the patients’ birthday, sex, date of first symp-
toms and diagnosis, trigger factors, prodromal symp-
toms, frequency and localization of angioedema,
medication use and comorbidities. Patients answered the
questions retrospectively for the year 2012. Specific add-
itional clinical information was collected in a survey
conducted in 2013 and 2014 via direct contact with the
patient, the family physician, hospitals, or relatives. Be-
cause ethical approvals for detailed questionnaire of the
centers of Zürich and Basel were not available, a closing
evaluation of all data was possible for 104 patients of the
centers Lucerne and Berne.
Data handling
Clinical information was collected in each center and
then transmitted to the administration site of the
Swiss HAE cohort (Haematology of the Cantonal
Hospital Lucerne). The information collected in the
survey was screened and checked for plausibility by
one researcher and then added to the electronic data-
base. The cohort database is maintained by one re-
searcher. If data were implausible or incomplete we
contacted the patient or his / her caregiver for clarifi-
cation. The final dataset was then pseudonymised and
prepared for analysis. The pseudonymisation key is
stored at the administration site.
Statistical analysis
We summarized variates with means and standard devi-
ations or percentages where appropriate. Associations
between female gender and presence of prodromal
symptoms (yes/no) were assessed in multivariate ana-
lyses correcting for patients’ age. The association be-
tween overall number of attacks and attacks on the
abdomen were assessed using mixed linear models en-
tering an indicator variate for the patient id as random
factor. Also, we assessed whether the age at diagnosis
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was associated with the reported number of attacks.
Analyses were performed using the Stata 14.1 statistics
software package. (StataCorp. 2015. Stata Statistical Soft-
ware: Release 14. College Station, TX: StataCorp LP.).
Results
The analysis was based on 104 consenting patients (57
women and 47 men) with a mean age of 44.0 years (SD
19.8) who completed the questionnaire referring to
2012. Hundred and two patients were affected by C1-
INH-HAE type I, 2 by type II.
The mean age at symptom onset was 11 years (SD
8.2). In men it was 9 years (SD 9.2) three years earlier
than in women with 12 years (SD 7.6). For details please
see Table 1. The average delay from the first symptoms
until diagnosis in patients without a family history of the
disease was 14 years (SD 11) for both women and men.
Frequency and localization of angioedema
The gender-related frequency of angioedema is shown in
Table 2. Women had more symptoms than men (45/57
vs. 33/47; p = 0.005) also when correcting for age at diag-
nosis (16.10. 95%CI (5.17 to 26.70); p = 0.004). Only 12
female and 14 male patients reported to be symptom
free in the preceding year. Swelling episodes ranged be-
tween 1 and 136 episodes/year and was more common
among female than among male (-13.15 (95 % CI; -23.10
to -3.22), p = 0.010). The localizations of angioedema oc-
curred is shown in Table 3. Overall, attacks occurred
most often on the abdomen (43 % cases), followed by
the extremities, cerebral angioedema (headache), trunk,
genitals, face and larynx. Age at diagnosis was inversely
associated with the total number of attacks 0.50 (-0.88
to -.011); p = 0.012).
Prodromal symptoms and trigger factors
Prodromal symptoms like fatigue, nausea, skin erythema,
local paresthesia or itching, which may precede angio-
edema were reported by 51 % of women and 43 % of
men (p = 0.397).
Eighty-one percent of female and 66 % of male respon-
dents stated that trigger factors preceded angioedema at-
tacks (Table 4).
Table 1 Characteristics of 104 patients completing the
questionnaire
Parameter Frequency / mean (SD)
women / men 57 / 47
mean age (years) 44 (SD 19.8; range 5 - 80)
mean age women (years) 44 (SD 19.8; range 13 - 80)
mean age men (years) 41 (SD 19.7; range 5 – 72))
age groups
≤10 years 3
11 – 20 years 12
21 – 30 years 17
31 – 40 years 14
41 – 50 years 18
51-60 years 21
≥60 years 19
symptom onset
mean age symptom onset 11 (SD 8.2)
mean age symptom onset women 12 (SD 7.6)
mean age symptom onset men 9 (SD 9.2)
delay of diagnosisa 14 (SD 10.9)
delay of diagnosisa women n = 37: 14 (SD 10.3)
delay of diagnosisa men n = 21: 14 (SD 12.3)
HAE variants
Type I 102
Type II 2
aaffected people with unknown family history
n number
Table 2 Gender-related number of attacks of angioedema for
2012
Total Women Men
Patients 104 57 47
symptomatic patientsa 78 45 33 p = 0.563
number of angioedema attacks 1770 1290 480 p = 0.015
≥1/weekb 10 8 2
≤1/week; ≥ 1/monthc 30 22 8
≤1/month; ≥ 1/yeard 38 15 23
aSymptomatic: all patients who experienced angioedema in 2012;
asymptomatic: all patients who didn’t experience angioedema in 2012
bfrequent number of attacks
cintermediate number of attacks
drare number of attacks
Table 3 Gender-related localization and number of
angioedema in 2012
women (57) men (47)
n of patients n of AE n of patients n of AE
abdomen 40 (70.%) 575 28 (59.%) 191
extremities 34 (60 %) 312 27 (57.%) 118
headache 11 (19 %) 186 5 (11 %) 43
trunk 15 (26.%) 89 7 (15 %) 37
genitals 11 (19 %) 70 11 (23.%) 35
face 14 (24.%) 41 8 (17 %) 33
larynx 9 (16 %) 17 7 (15 %) 23
Percentages are related in women to the total amount of women, in men to
the total amount of men
n number
AE Angioedema
Steiner et al. Orphanet Journal of Rare Diseases  (2016) 11:43 Page 3 of 8
Therapy
In Switzerland danazol and tranexamic acid (TA) are
used for prophylactic treatment, whereas plasma - de-
rived C1-Inhibitor (pd C1-INH) and Icatibant are ad-
ministered for treatment of acute attacks. Some patients
practice individual replacement therapy (IRT), which
means that they administer pd C1-INH on demand very
early when prodromal symptoms appear before an acute
angioedema attack [16].
One third of patients were on prophylaxis. Danazol
was used by 23 % of women and 27 % of men at doses
of 100 mg twice a week to 200 mg daily. TA was taken
by 10 % of women and 8 % of men with daily doses from
500 mg to 4000 mg. IRT was practiced by 7 women and
2 men.
In the event of an acute attack pd C1INH was admin-
istered to 56 % of women and 53 % of men, whereas
16 % of women and 6 % of men administered Icatibant.
(Table 5).
The frequency of angioedema episodes in 2012 with or
without prophylaxis/IRT is shown in Table 6. Without
prophylaxis, women suffered from 835 angioedema epi-
sodes (22/woman) and men from 216 (7/man). Women
on danazol experienced 143 attacks (11/woman) and
men on danazol 64 (5/man). Six women and 4 men
using danazol had no attacks during the study period.
Comparing gender-related localization of angioedema
when on prophylactic treatment with danazol, women
suffered from fewer symptoms on all locations, with the
exception of the trunk, face and brain (headache)
(Table 7).
Among the patients on TA, one woman and one man
were asymptomatic, one man suffered from frequent at-
tacks (≥1/week) one man and two women from inter-
mediate attacks (≤1/week; ≥ 1/month), and three women
and one man from rare attacks (≤1/month; ≥ 1/year).
Two women on IRT suffered from frequent attacks, four
women and one man from intermediate, and one each
from rare attacks.
Three different forms of treatment were practiced:
Oral (Danazol, TA), intravenous (pd C1 INH), and sub-
cutaneous (Icatibant). C1INH home therapy was prac-
ticed by 23 women and 15 men. The family doctor
performed the therapy for 10 women and 5 men. Hos-
pital treatment was required for 8 women and 4 men.
Of the 30 patients who experience more than 1 attack/
month, 16 were able to administer C1INH on their own
at home. Two hundred and forty-eight swelling episodes
were not treated by 21 women and 16 men.
Comorbidities
The patients were asked about their medication intake
other than HAE-related drugs. Specific medication
allowed conclusion to be drawn about the diagnosis of
other diseases than HAE. Thirty-two per cent, (20
women and 13 men) were affected by comorbidities
(Table 8). Arterial hypertension was the most frequent
disorder with 22 % (14 women, 9 men) followed by dys-
lipidemia at 5.7 % (5 women, 1 man). Patients with
danazol-prophylaxis suffered with 54 % (9 women, 5
men) from more comorbidities compared to the 24 %
(11 women, 8 men) without danazol prophylaxis.
Discussion
In this study we described the gender-related clinical
and therapeutic characteristics of the great majority of
Swiss HAE patients. Women were more affected by in-
tensity and frequency of angioedema episodes than men,
which is in line with a previous report [13]. This is most
probably related to the exogenous and endogenous es-
trogen in puberty, ovulation during the menstrual cycle,
estrogen-based birth control pills, or estrogen replace-
ment therapy [17].
Prodromal symptoms and trigger factors
About half of the patients, mainly women, noticed pro-
dromal symptoms once in their lives. This awareness to
perceive oncoming attacks enables the patients to start
therapy early, which in turn leads to a quicker treatment
response [18].
The proportion of patients reporting the perception of
trigger factors corroborates the data recently described
by Zotter and colleagues [19]. Mental stress, mechanical
Table 4 Trigger factors
Trigger factor Number of patients women men
All 77 46 31
Emotions 53 33 (72 %) 20 (64 %)
Trauma / Mechanical trigger 47 27 (59 %) 20 (64 %)
Foodstuff / allergies 33 20 (43 %) 13 (42 %)
Infection 21 13 (28 %) 8 (26 %)
Hormones 35 34 (74 %) 1 (3 %)
None 27 11 (24 %) 16 (57 %)
Percentages relate to the total of women or men who noticed trigger factors
Table 5 Therapeutic modalities in 2012 (n = 104)
Pharmacological prophylaxis women and men women men
tranexamic acid 10 6 (10 %) 4 (8 %)
danazol 26 13 (23 %) 13 (27 %
IRT
pd C1 - INH 9 7 (12 %) 2 (4 %)
Therapy of acute attacks
Icatibant 12 9 (16 %) 3 (6 %)
pd C1 – INH 57 32 (56 %) 25 (53 %)
Percentages are related in women to the total amount of women, in men to
the total amount of men
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trauma and physical exertions are the most relevant trig-
ger factors for both genders, followed by food and infec-
tions. Foodstuff as a trigger factor is also described by
Zotter et al. If it is intolerance or allergy which induces
angioedema has to be elucidated in further studies. In
our study, a large variety of different foodstuff was re-
ported, including milk products, fruit, seafood and nuts.
Endogenous or exogenous estrogen is an exclusive and
the most important trigger factor for women. Female
were more prone to mental stress than men, physical
and mechanical exertion were a more relevant trigger in
men (Table 4). These results could indicate that women
have a different coping with stress than men, whereas
men are more exposed to physical/mechanical exertion.
We speculate that women have a better self–perception
enabling them to recognize prodromal symptoms and
trigger factors better than men.
Frequency and localization of angioedema
Regardless of gender, the abdomen was the most affected
body part, followed by the extremities. In other cohorts
this was the opposite [13, 20]. Compared to men, women
suffered from more attacks to all localizations except the
genitals and larynx. The constitutional exposure of
Table 6 Frequency of attacks with or without prophylaxis / IRT in 2012
Number of Angioedema attacks
no attacks ≥1/weeka ≥1/month≤ 1/weekb ≥1/year≤ 1/monthc Total n of AE
Women and men 104 26 10 30 38 1770
Women All 57 12 8 22 15 1290
prophylaxis None 38 5 7 18 8 835
Danazol 13 6 1 2 4 143
TA 6 1 0 2 3 48
IRT C1-INH 7 0 2 4 1 264
men All 47 14 2 8 23 480
prophylaxis None 30 9 1 5 15 216
Danazol 13 4 0 2 7 64
TA 4 1 1 1 1 78
IRT C1-INH 2 0 0 1 1 122
afrequent number of attacks; bintermediate number of attacks; crare number of attacks
n number, AE Angioedema
no attacks: asymptomatic for the year 2012
Table 7 Prophylaxis with danazol and comparison of location-related symptoms between women and men in 2012
Location
of attacks
All Women no prophylaxis vs.
Danazol
Men no prophylaxis vs.
Danazol
women vs.
men
All No
prophylaxis
Danazol p-values All No
prophylaxis
Danazol p-values p-values
104 57 31 13 47 28 13
abdomen 68 (65 %) 40 (70 %) 24 (77 %) 6
(46 %)
p = 0.042 28
(59 %)
15 (53 %) 9
(69 %)
p = 0.344 p = 0.063
extremities 61 (59 %) 34 (60 %) 20 (64 %) 5
(38 %)
p = 0.111 27
(57 %)
14 (50 %) 8
(61 %)
p = 0.491 p = 0.157
trunk 22 (21 %) 15 (26 %) 8 (26 %) 3
(10 %)
p = 0.849* 7
(15 %)
4 (14 %) 0 p = 0.288* p = 0.523*
face 22 (21 %) 14 (24 %) 8 (26 %) 2 (6 %) p = 0.697* 8
(17 %)
4 (14 %) 1 (8 %) p = 0.486** p = 0.709**
genitals 22 (21 %) 11 (19 %) 8 (26 %) 1 (3 %) p = 0.242* 11
(23 %)
5 (18 %) 3
(23 %)
p = 0.692* p = 0.586*
headache 16 (15 %) 11 (19 %) 4 (13 %) 3
(10 %)
p = 0.404* 5
(11 %)
4 (14 %) 0 p = 0.288* p = 0.509*
larynx 16 (15 %) 9 (16 %) 6 (19 %) 1 (3 %) p = 0.654 7
(15 %)
4 (14 %) 1 (8 %) p = 0.486** p = 0.700**
* Fisher’s exact test, ** one-sided
Number of patients who suffered from at least one attack in the individual location in 2012
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genitals could explain why angioedema of this region
occur more often in male. In order to identify the reasons
for the more common laryngeal swellings in men, one can
only guess that pharyngeal/laryngeal irritation by airway
infections [19], snoring [21] or smoking [22] are relevant
triggers.
Gender related efficacy of danazol prophylaxis
Prophylactic danazol therapy is widely used in HAE-
treatment. Its efficacy is well known, as are its side ef-
fects [23]. Danazol, on one hand, stimulates the liver to
synthesize C1-INH and enhances the expression of C1-
INH mRNA in peripheral blood mononuclear cells [24].
On the other hand, as a weak androgen, danazol has an
antigonadotropic effect and inhibits ovarial estrogen
production. If the daily dosage does not exceed 200 mg
and treatment is closely monitored for possible side ef-
fects such as virilisation, hepatic diseases, arterial hyper-
tension and dyslipidemia, it is a reasonable therapy for
adult patients and those women who are neither preg-
nant nor breast-feeding [15, 25–29]. Development of
liver cell adenomas or even hepatocellular carcinomas
on long term therapy with danazol are uncommon [30,
31].
Comparing danazol prophylaxis between women and
men, it seems that the drug has a better and different ef-
fect in women than in men.
Women on danazol suffered from fewer attacks to the
abdomen and extremities than men on danazol (Table 7).
It can be assumed that the hormonal modulating effect
of danazol with suppression of gonadotropin and re-
duced estrogen production leads to a decreased stimula-
tion of the contact activation pathway and consecutively
to a decreased bradykinin production, which is essential
in this prophylactic therapy. The high therapeutic effi-
cacy of danazol in women could also explain why an im-
portant part of women (23 %) are on danazol
prophylaxis despite a higher frequency of side effects.
Comorbidities
In this cohort, patients on danazol suffer from more co-
morbidities (54 %) compared to those without prophy-
laxis (24 %). Women on danazol were more affected by
comorbidities than men on danazol (69 % vs 38 %). Da-
nazol treatment showed a clear association with
Dyslipidemia.
Therapy of attacks
Attacks were treated with pd C1-INH in 55 % of cases.
Only few used Icatibant. The reason for this might be
that Icatibant has not been on the Swiss market long
enough (since 2009) and patients require a certain time
to gain trust in new therapies. On the other hand, ther-
apy with C1-INH seems to be more sustainable for pa-
tients with frequent attacks.
About two-thirds of patients using C1-INH practice
home treatment after being carefully instructed in a
HAE– center [32]. Offering home therapy and self-
Table 8 Comorbidities
Co-morbidities All patients Patients without danazol Patients on danazol
w m w m w m
All 104 57 47 78 44 34 26 13 13
No comorbidities 7168 % 3765 % 3472 % 5672 % 3375 % 2676 % 1246 % 431 % 861 %
Comorbidities 3332 % 2035 % 1328 % 1924 % 1125 % 823 % 1454 %% 969 % 538 %
Arterial Hypertension 2322 % 1424 % 919 % 1114 % 614 % 515 % 1246 % 861 % 431
Dyslipidemia 66 % 59 % 12 % 0 0 0 623 % 538 % 12 %
DVT 44 % 12 % 36 % 22 % 0 26 % 28 % 12 % 1
Depression 44 % 23 % 24 % 22 % 12 % 13 % 28 % 1 1
CHD 44 % 35 % 12 % 45 % 37 % 13 % 0 0 0
CVI 10.9 % 0 12.1 % 0 0 0 13.8 % 0 1
PAD 11 % 0 12 % 11 % 0 12.9 % 0 0 0
Diabetes mellitus 55 % 47 % 12 % 34 % 24 % 13 % 28 % 215 % 0
Epilepsy 11 % 12 % 0 11 % 12 % 0 0 0 0
Schizophrenia 11 % 0 12 % 0 0 13 % 0 0 0
Parkinson’s disease 22 % 23 % 0 11 % 12 % 0 14 % 1 0
Hypothyroidism 22 % 12 % 12 % 1 % 12 % 0 14 % 0 1
COPD/Asthma 22 % 23 % 0 22 % 24 % 0 0 0 0
Osteoporosis 22 % 23 % 0 22 % 24 % 0 0 0 0
CHD Coronary heart disease, CVI Cerebrovascular Insult, DVT deep venous thrombosis, PAD peripheral artery disease
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treatment to all HAE patients is a goal worth striving
for. It’s the best way of optimizing treatment for a dis-
order with highly individual symptoms, improving qual-
ity of life with fewer and less severe attacks. As they do
not require medical facilities, their medicare costs also
decrease. Against doctors’ recommendation, 14 % of
acute attacks were not treated at all. This is most likely
because of an attitude that attacks that do not seem to
be life-threatening do not require treatment.
Conclusion
The aim in treating HAE-affected people is to minimize
their swelling episodes in the best possible manner with
the limited therapeutic options. First and foremost, the
treating physician should be aware that symptoms vary
across individuals and that women suffer from a more
severe disease activity than men. The therapy plan must
include careful training in self-perception to recognize
prodromal symptoms and trigger factors and a training
in administering self-therapy for acute swelling episodes.
This should lead to lifestyle adaption by avoiding triggers
as much as possible and individualizing the treatment
with early start of therapy according to prodromal symp-
toms and acute attacks. This gives the patient indepen-
dency and more self-responsibility. Danazol, as an
efficient prophylaxis, requires close supervision of side
effects. Women seem to have a better benefit from dana-
zol than men, but also suffer from more side effects. But
this assumption should be confirmed in a prospective
study comparing genders and frequency of angioedema
before and with danazol. New therapies which selectively
influence the hormonal estrogen balance could open
new therapeutic options mainly for women and maybe
also for men.
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